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Abstract L-Histidine decarboxylase (HDC) is a dimer consist-
ing of two identical 53 kDa subunits. On the other hand, the size 
of HDC deduced from its cDNA sequence is around 74 kDa, 
indicating that the translated 74 kDa form of HDC is subjected 
to post-translational processing to generate the 53 kDa form. 
However, modification of the translated 74 kDa form of HDC in 
histamine-forming cells is unknown. Here we demonstrate that 
the 74 kDa form is translated in rat basophilic leukemia cells, 
followed by conversion to the 53 kDa form, and that the 74 kDa 
form is a short half-life protein because of the degradation 
mediated by the ubiquitin-proteasome pathway. Degradation of 
the 74 kDa form was stimulated in the presence of an ATP-
generating system, accompanied by ubiquitination, and inhibited 
by specific proteasome inhibitors such as ZL3H and lactacystin. 
A significant amount of proteasome activity was detected in 
RBL-2H3 cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
L-Histidine decarboxylase (HDC: EC 4.1.1.22) is a key en-
zyme in histamine formation in mammals. HDC has been 
purified and characterized from the soluble fraction of various 
tissues and cells [1-4]. The purified enzyme comprises a ho-
modimer, composed of two identical 53-55 kDa subunits. On 
the other hand, cloning of the cDNAs for the enzyme has 
indicated that the initial translated products are all around 
74 kDa [5-7]. We have demonstrated that the recombinant 
mouse 74 kDa form of HDC, present in the particulate frac-
tion of Sf9 cells, exhibits a low catalytic activity [8], and is 
cleaved by in vitro incubation with porcine pancreatic elastase 
to yield a 53 kDa form with full enzymatic activity in the 
soluble fraction [9]. However, there has been no demonstra-
tion of the existence of the 74 kDa form of HDC, and no data 
on the proteolytic cleavage of the 74 kDa form into the 53 
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kDa form in vivo. Therefore, the first aim of this study was to 
investigate the existence of the 74 kDa form and its conver-
sion to the 53 kDa form in a rat basophilic leukemia cell line, 
RBL-2H3. 
Very recently, it has been clarified that the ubiquitin-pro-
teasome system plays an important role in the degradation of 
short half-life growth regulators such as cyclin and cyclin-
dependent kinases, translational activators and inhibitors, 
and a few enzymes such as tyrosine aminotransferase and 
ornithine decarboxylase (ODC) [10,11]. ODC is a key enzyme 
in the regulation of intracellular polyamine levels and cell 
growth [12-14]. The enzyme is induced by several stimuli 
[13] and is subject to rapid degradation by the 26S proteasome 
pathway without ubiquitination [15]. Degradation of a protein 
through this system involves two successive steps: sequential 
conjugation of ubiquitin molecules to the target protein and 
degradation of the protein by the 26S proteasome complex via 
an ATP-dependent reaction. For the ubiquitin-proteasome 
system, the putative required sequences are the PEST regions 
in the target molecule, which are found in extremely short 
half-life eukaryotic proteins, hydrophilic sequences enriched 
in Pro, Ser/Thr or Asp/Glu residues flanked by positively 
charged residues. Detailed structural analysis of the rat 
HDC cDNA sequence revealed that three PEST regions are 
present in the translated protein one near the N-terminus and 
two at the C-terminus of the molecule. In about 21 kDa of the 
C-terminal region of the 74 kDa form of rat HDC two PEST 
regions are present, and this region should be cleaved off 
during post-translational processing [5,7,8]. Thus, we show 
that the 74 kDa form and not the 53 kDa form was degraded 
by the ubiquitin/ATP-dependent pathway in RBL-2H3 cells, 
the degradation being inhibited by proteasome inhibitors. 
2. Materials and methods 
2.1. Materials 
Anti-GST-fusion HDC antiserum was prepared as described previ-
ously [16]. The following materials were purchased from the sources 
indicated: leupeptin and aprotinin from Wako Pure Chemicals (To-
kyo, Japan), «-acetyl leucyl leucyl norleucinal (ALLN) and n-acetyl 
leucyl leucyl methional (ALLM) from Sigma (St. Louis, MO, USA), 
carboxybenzyl leucyl leucyl leucinal (ZL3H), carboxybenzyl leucyl 
leucyl leucyl 4-methyl-coumaryl-7-amide (z-leu-leu-leu-MCA) and car-
bobenzoxy leucyl leucinal (ZL2H) from Peptide Institute (Osaka, Ja-
pan), PVDF membranes from Millipore (Tokyo, Japan), mouse anti-
ubiquitin monoclonal antibody from Chemicon International Inc. 
(Temecula, CA, USA), peroxidase-conjugated anti-mouse IgG 
from Dako (Glostrup, Denmark), ECL Western blot detection 
reagent from Amersham Life Science (Buckinghamshire, UK), 
[35S]methionine (1000 Ci/mmol) from Du Pont-New England Nuclear 
(Boston, MA, USA) and protein A-Sepharose CL-4B and NAP-5 
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columns from Pharmacia Biotech (Uppsala, Sweden). All other chem-
icals were commercial products of reagent grade. 
2.2. Cell culture 
RBL-2H3 cells were grown in RPMI 1640 medium supplemented 
with 10% fetal calf serum (complete medium) in 5% C0 2 at 37°C in a 
fully humidified atmosphere. Exponentially growing cells were used in 
all experiments. 
2.3. Biosynthetic labeling 
Cells were starved for 30 min in methionine-free RPMI 1640 me-
dium supplemented with 10% dialyzed fetal calf serum and then sub-
jected to pulse labeling with [35S]methionine (10 uCi/ml) for the times 
indicated. In chase experiments after pulse labeling, cells were rinsed 
once in complete medium and incubated for the times indicated. 
2.4. Immunoprecipitation 
[35S]Methionine-labeled cells were harvested and washed twice in 
PBS. The cell pellet was suspended in 1 ml of RIPA buffer (30 mM 
HEPES-NaOH, pH 7.3, containing 150 mM sodium chloride, 1% 
Triton X-100, 1% deoxycholate and 0.1% SDS) and incubated on 
ice for 1 h. For protection against proteolytic degradation, a mixture 
of protease inhibitors (0.2 mM PMSF, 100 uM benzamidine, 10 |J.g/ml 
leupeptin, 10 itg/ml aprotinin, 10 ug/ml E-64 and 1 ug/ml pepstatin A) 
was added. The mixture was then centrifuged at lOOOOXg for 10 min 
at 4°C. 50 u.1 of protein A-Sepharose CL-4B (1:1 slurry) was added to 
the resulting supernatant and incubated for 1 h at 4°C. The mixture 
was centrifuged at 8000 Xg for 5 min at 4°C. Anti-GST-fusion HDC 
antiserum was added to the resulting supernatant (1:200) and then 
incubated for 1 h at 4°C. 50 ul of protein A-Sepharose CL-4B was 
added to the mixture and incubated for 1 h at 4°C. The mixture was 
recentrifuged at 8000Xg for 5 min at 4°C, and the resulting precip-
itate was washed five times with 1 ml of RIPA buffer. The immuno-
precipitate was resuspended in an equal volume of 2XSDS sample 
buffer (125 mM Tris-HCl, pH 6.8, containing 4% SDS, 10% 2-mer-
captoethanol, 20% glycerol and 0.1% bromophenol blue) and boiled 
for 15 min. The sample was subjected to SDS-PAGE (10% slab gel) 
according to the method of Laemmli [17]. The gel was dried and 
analyzed with a Fujix BAS 2000 Bio-Imaging Analyzer. 
2.5. Immunoblot analysis 
The immunoprecipitate prepared with anti-GST-fusion HDC anti-
serum was subjected to SDS-PAGE (7% slab gel) and the separated 
proteins were transferred electrophoretically to a PVDF membrane in 
25 mM Tris base containing 40 mM 6-aminohexanoic acid, 0.02% 
SDS and 20% methanol at room temperature for 90 min at 15 V. 
The membrane was rinsed in Tris-buffered saline (TBS; 20 mM Tris-
HCl, pH 7.5, containing 150 mM NaCl) and then preincubated over-
night in TBS containing 5% non-fat milk at 4°C. The membrane was 
then incubated with anti-ubiquitin (1:1000) antibody in TBS contain-
ing 5% non-fat milk for 1 h at 37°C. The membrane was washed three 
times with TTBS (TBS containing 0.05% Tween-20) at room temper-
ature. The membrane was incubated with peroxidase-conjugated anti-
mouse IgG in TTBS for 1 h at room temperature, and then stained 
with the ECL Western blot detection reagent. 
2.6. In vitro degradation of 74 kDa HDC 
The cells labeled with [35S]methionine for 30 min were homogen-
ized, using a Teflon-glass homogenizer, with 40 strokes in the lysis 
buffer (10 mM HEPES-NaOH, pH 7.3, containing 1.5 mM MgC12, 10 
mM KC1, 0.5 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA and the 
mixture of protease inhibitors). The homogenate was centrifuged at 
lOOOXg for 10 min at 4°C and then the resultant supernatant was 
recentrifuged at lOOOOXg for 30 min at 4°C. The supernatant ob-
tained was desalted using a NAP-5 column. The desalted supernatant 
was incubated for 10 min at 37°C in the (—) ATP buffer (the lysis 
buffer containing 2 mM ATPyS) and in the (+) ATP buffer (the lysis 
buffer containing 2 mM ATP, 1 mM creatine phosphate and 37.5 ug/ 
ml creatine phosphokinase). The reaction was stopped by adding 1/5 
the volume of 5 X RIPA buffer containing a 5 X concentration of the 
mixture of protease inhibitors, and then it was subjected to immuno-
precipitation analysis as described above. 
3. Results 
3.1. Conversion of the [S5S]methionine-labeled 74 kDa form 
into the 53 kDa form of HDC in RBL-2H3 cells 
The synthesis of the 74 k D a and 53 k D a forms of H D C was 
separately analyzed by pulse labeling study (Fig. 1A) and 
conversion of the former to the latter form by pulse-chase 
study (Fig. IB) in RBL-2H3 cells. The radioactive 74 k D a 
form of H D C was detected within 2 min of pulse labeling 
and its level increased to a maximum level by 30 min. On 
the other hand, the radioactive 53 k D a form of H D C ap-
peared 10 min after pulse labeling and its level gradually in-
creased. Furthermore, the pulse-chase study revealed conver-
sion of the radioactive 74 k D a form to its 53 k D a form. The 
Fig. 1. Time-dependent formation of the 74 kDa and 53 kDa forms of HDC. RBL-2H3 cells (1X107 cells/lane) were pulsed with 
[35S]methionine for the time periods indicated (A), and chased (pulse for 10 min) for the times indicated in the presence of an excess amount 
of cold methionine (B) before lysis in RIPA buffer and immunoprecipitation with anti-GST-fusion HDC antiserum. The immunoprecipitates 
were analyzed by SDS-PAGE and with a Fujix BAS 2000 Bio-Imaging Analyzer. The 74 kDa HDC and 53 kDa HDC are indicated by the ar-
rows. 
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Fig. 2. Effect of protease inhibitors on the degradation of 74 kDa 
HDC. RBL-2H3 cells (1 X107 cells) were incubated with or without 
various protease inhibitors for 3 h, and pulsed with [35S]methionine 
for 10 min (lanes 1, 3, 5, 7, 9, 11 and 13) followed by a chase for 
90 min (lanes 2, 4, 6, 8, 10, 12 and 14). The immunoprecipitated 
HDCs were analyzed by SDS-PAGE and a Fujix BAS 2000 Bio-
Imaging Analyzer. Column A shows the effects of various protease 
inhibitors; lanes 1 and 2, no treatment; 3 and 4, aprotinin (5 |ig/ 
ml); 5 and 6, leupeptin (5 u.g/ml); 7 and 8, benzamidine (10 U.M); 9 
and 10, PMSF (2 uM); 11 and 12, E-64 (5 Ug/ml); 13 and 14, pep-
statin A (1 ug/ml). Column B shows the effects of proteasome inhib-
itors; lanes 1 and 2, no treatment; 3 and 4, ZL3H (20 itM, pre-
treated for 30 min); 5 and 6, lactacystin (10 uM, pretreated for 3 h); 
7 and 8, ALLN (100 uM, pretreated for 30 min); 9 and 10, ZL2H 
(20 uM, pretreated for 30 min). Column C shows the effects of 
ZL3H and ZL2H by pulse-chase study. Cells (1X 107 cells/lane) were 
pulsed for 10 min and chased for the time periods indicated. 30 min 
before pulse labeling, 20 |xM ZL3H and 20 |xM ZL2H and dimethyl-
sulfonyloxide (solvent alone) were added to the culture medium. Im-
munoprecipitated HDCs were analyzed. 
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amount of the radioactive 74 kDa form synthesized during the 
10 min of pulse labeling, sharply reduced to a negligible level 
over 60 min of pulse chasing. In turn the radioactive 53 kDa 
form consistently accumulated up to 30 min, and reached a 
plateau level by 6 h. These profiles of conversion in a 10 min 
pulse study were basically reproduced in a 30 min pulse study 
(data not shown). 
3.2. Effect of proteasome inhibitors on the degradation of 
74 kDa HDC 
To determine the mechanism of the sharp decrease in the 
level of the 74 kDa form, we clarified whether the degradation 
of the radioactive 74 kDa form is sensitive to specific protein-
ases. For identification of the possible proteinase involved, 
various proteinase inhibitors were added to cells before treat-
ment with a radioactive pulse for 10 min followed by a chase 
for 90 min. The radioactive 74 kDa form after the chase was 
compared for each proteinase inhibitor used. The degradation 
of the 74 kDa form was largely inhibited in the presence of 
proteasome inhibitors (Fig. 2B), such as ZL3H (lane 3 vs. 4), 
ALLN (lane 5 vs. 6), and lactacystin (lane 7 vs. 8), and 
slightly by ZL2H (lane 9 vs. 10) which is a weak inhibitor 
of proteasome but a potent calpain inhibitor [18]. However, 
no significant effects were observed using other proteinase 
inhibitors, such as aprotinin, leupeptin, benzamidine, PMSF, 
E-64 and pepstatin A (Fig. 2A) or chloroquine, an inhibitor of 
lysosomal protein degradation (data not shown). As shown in 
Fig. 2C, the addition of ZL3H and ZL2H also increased the 
accumulation of the radioactive 74 kDa form, but the latter 
showed short-term activity compared to the former. 
3.3. Ubiquitination of 74 kDa HDC 
In order to investigate the involvement of ubiquitin conju-
gation in the degradation of the 74 kDa form of HDC, we 
analyzed the formation of high molecular weight ubiquitin-
HDC adductants. The smear bands of polyubiquitinated 
HDC adductants, having an estimated molecular weight of 
over 150 kDa, which were immunoprecipitated by anti-GST-
fusion HDC antibody and detected with anti-ubiquitin anti-
body, were marked in the presence of ZL3H (Fig. 3A). The 
smear bands comprised radioactive HDC formed during pulse 
labeling (Fig. 3B). 
Fig. 3. Ubiquitination of 74 kDa HDC. RBL-2H3 cells (5X107 cells) were pretreated with (+) or without (-) 20 uM ZL3H for 30 min, and 
pulse-labeled with [35S]methionine for 30 min and immunoprecipitated with anti-GST-fusion HDC antiserum. Immunoprecipitates were sub-
jected to SDS-PAGE (7% slab gel), and separated proteins were transferred to PVDF membrane, and immunoblotted with anti-ubiquitin anti-
body (1:1000) as described in Section 2. A: Immunoblot analysis with anti-ubiquitin antibody. TgG' indicates antibody used in immunoprecipi-
tation (anti-GST-fusion HDC antiserum). B: Autoradiography of the same blot as in A. The blot was analyzed using a Fujix BAS 2000 Bio-
Imaging Analyzer. The arrows indicate the 74 kDa and 53 kDa forms of HDC. The star indicates a non-specific band. 'poly-Ub' indicates 
poly-ubiquitinated 74 kDa HDC. 
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Fig. 4. ATP dependence of the degradation of 74 kDa HDC in vi-
tro. RBL-2H3 cells (1 X107 cells/lane) labeled with [35S]methionine 
for 30 min were homogenized and fractionated by centrifugation as 
described in Section 2. A: Radioactive 74 kDa and 53 kDa HDC in 
the lOOOOXg supernatant (lane 1) and precipitate fraction (lane 2) 
after immunoprecipitation with anti-GST-fusion HDC antiserum. B: 
Changes in radioactive 74 kDa HDC in aliquots of the lOOOOXg 
supernatant which were incubated for 10 min at 37°C with (lanes 4 
and 5) or without (lanes 2 and 3) 20 uM ZL3H. The supernatant 
was incubated in the (—) ATP buffer (the lysis buffer containing 
2 mM ATPyS) (lanes 2 and 4) and in the (+) ATP buffer (the lysis 
buffer containing 2 mM ATP, 1 mM creatine phosphate and 37.5 
ug/ml creatine phosphokinase) (lanes 3 and 5). Lane 1 is the control 
without incubation. The arrows indicate the 74 kDa and 53 kDa 
forms of HDC. 
3.4. ATP dependence of the degradation of 74 kDa HDC in 
vitro 
To determine whether the degradation of the 74 kDa form 
of HDC is energy-dependent, the radioactive 74 kDa form in 
the supernatant fraction obtained by centrifugation at 
lOOOOXg for 60 min was treated with or without an ATP-
generating system in the presence or absence of ZL3H in vitro. 
The lOOOOXg supernatant fraction of the cells contained the 
majority of the 74 kDa form (Fig. 4A, lane 1), and the 
lOOOOXg precipitate contained the 53 kDa form. During 
the incubation for 10 min at 37°C, the level of the radioactive 
74 kDa form was not changed substantially in the presence of 
ATP7S, but was apparently decreased in the presence of the 
ATP-generating system (Fig. 4B, lane 2 vs. 3). This ATP-de-
pendent degradation of the 74 kDa form was partially re-
duced by addition of ZL3H (lane 3 vs. 5). 
3.5. Proteasome activity in the extract of RBL-2H3 cells 
To confirm that RBL-2H3 cells contain proteasome activ-
ity, we assayed the hydrolysis of z-leu-leu-leu-MCA, a prefer-
ential substrate of the proteasome [19]. The lOOOOXg super-
natant of the cells exhibits a significant amount of hydrolytic 
activity (148 ±24.0 nmol/min/107 cells) which was completely 




Recent studies have suggested that the proteasome pathway 
is involved in the selective degradation of many important 
proteins such as muscle proteins, cell cycle regulatory pro-
teins, transcription factors, and enzymes such as tyrosine ami-
notransferase and ODC [10,11]. Proteasome catalyzes an en-
ergy-dependent, non-lysosomal proteolytic pathway. Here we 
demonstrated that the degradation of the 74 kDa form of 
HDC in RBL-2H3 cells was ATP-dependent, under the ubi-
quitin-conjugated pathway, and sensitive to proteasome inhib-
itors. These results, together with the significant activity of 
proteasome in RBL-2H3 cells, demonstrated that the 74 
kDa form is a short half-life protein because of its rapid 
degradation via the proteasome pathway. Compared to the 
74 kDa form, the 53 kDa form seems to be relatively stable 
(Fig. IB). As shown in Fig. 4, the 74 kDa form is localized 
primarily in the cytosol and partially in the particulate frac-
tion, whereas the 53 kDa form is mostly located in the partic-
ulate fraction, which has been revealed to consist of the en-
doplasmic reticulum (ER), Golgi and granules (data not 
shown). In contrast to the present study, we previously re-
ported that the expressed recombinant 74 kDa form of 
HDC in Sf9 cells was mostly recovered in the particulate 
fraction [8]. Considering the rapid degradation of the 74 
kDa form, it is possible that the precipitated recombinant 
74 kDa form of HDC in Sf9 cells is an abnormal form of 
protein similar to bacterial inclusion bodies, which have been 
reported in a bacterial system. Although the soluble recombi-
nant 54 kDa form of HDC was observed in Sf9 cells [8], this 
form may not reflect the nature of the 53 kDa form generated 
through post-translational processing of 74 kDa HDC in 
RBL-2H3 cells. 
Since the 74 kDa form lacks an amino-terminal signal se-
quence that is cleaved following translocation across the ER 
membrane [5], it may be synthesized by free ribosomes in the 
cytosol as a non-secreted protein. The existence of the partic-
ulate 53 kDa form means the targeting and conversion of the 
74 kDa form in the particulate fraction. As a result, the 74 
kDa form of HDC is subjected to metabolism via two distinct 
ways in the cytosol: targeting to the ER resulting in the for-
mation of the 53 kDa form and degradation via the ubiquitin-
proteasome pathway. A rapid decrease in the concentration of 
the radioactive 74 kDa form was not accompanied by an 
increase in the concentration of the 53 kDa form and the 
amount of 53 kDa form did not change during a chase period 
(Fig. IB). In addition, the pretreatment of proteasome inhib-
itors did not change the amount of the 53 kDa form (Fig. 2C). 
These results indicate that ubiquitin-proteasome pathway may 
not be involved in the conversion of the 74 kDa form into the 
53 kDa form. 
ODC, like HDC, is a very unstable protein [20] and is 
known to be degraded by the ATP/antizyme-dependent pro-
teasome pathway [21]. Recently, some common structural fea-
tures of ODC and HDC were identified [22]. These include the 
presence of PEST regions. PEST regions can act as constitu-
tive or conditional signals providing a means for the intra-
cellular degradation of key metabolic proteins [23]. Rat HDC 
has three PEST regions in its amino acid sequence [22]: one 
between amino acids 43-74 which is homologous to the PEST 
region in mouse and human HDC and two between amino 
acids 503-525 and 529-555 which are present in the C-termi-
nal region of the 74 kDa form but not in the 53 kDa form of 
HDC. The two PEST regions in the C-terminal region of the 
74 kDa form have a role in the degradation via the protea-
some pathway. The degradation of ODC is not dependent on 
ubiquitination [15], which is responsible for the degradation of 
HDC. Here we first demonstrated that HDC is degraded by 
proteolysis mediated by the ATP/ubiquitin-dependent protea-
some pathway. 
At present the reason for the existence of the two forms of 
HDC, the soluble 74 kDa form and the particulate 53 kDa 
form, in RBL-2H3 cells is unclear. The 74 kDa form may 
have a role in the production of cytosolic histamine which is 
spontaneously released or transported to histamine-containing 
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granules for storage, whereas the particulate 53 k D a form is [1°. 
convenient to directly synthesize granular histamine which is 
released in response to a receptor-mediated immune reaction. 
The function of cytosolic histamine remains to be clarified, [iz 
but it is possible that it is involved in the growth of some 
cell lines and tumors [24-26]. To test this hypothesis, it will I13 
be necessary to determine in detail the localization of two 
forms of H D C and the characteristics of the converting en- [14] 
zyme involved in the synthesis of the 53 k D a form from the 74 
k D a form of H D C . [ ^ 
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